Bio-Connect

IGF1R beta (phospho Tyr1316) antibody

GTX133448
GeneTex
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetIGF1R
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    IGF1R (phospho Tyr1316) antibody
  • Delivery Days Customer
    9
  • Antibody Specificity
    The full-length IGF1R includes the 30 aa signal peptide that is cleaved during maturation. The Tyr1316 of mature IGF1R is equivalent toTyr1346 of uncleaved IGF1R.
  • Application Supplier Note
    WB: 1:500-1:3000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    4 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID3480
  • Target name
    IGF1R
  • Target description
    insulin like growth factor 1 receptor
  • Target synonyms
    CD221; IGF-I receptor; IGFIR; IGFR; insulin-like growth factor 1 receptor; JTK13; soluble IGF1R variant 1; soluble IGF1R variant 2
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP08069
  • Protein Name
    Insulin-like growth factor 1 receptor
  • Scientific Description
    This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. [provided by RefSeq]
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Ovulatory Follicular Fluid Facilitates the Full Transformation Process for the Development of High-Grade Serous Carcinoma. Hsu CF et al., 2021 Jan 26, Cancers (Basel)
    Read more